Unda Villafuerte Fabián, Llobera Cànaves Joan, Lorente Montalvo Patricia, Moreno Sancho María Lucía, Oliver Oliver Bartolomé, Bassante Flores Patricia, Estela Mantolan Andreu, Pou Bordoy Joan, Rodríguez Ruiz Tomás, Requena Hernández Ana, Leiva Alfonso, Torrent Quetglas Matíes, Coll Benejam José María, D'Agosto Forteza Pilar, Rigo Carratalà Fernando
Coll D'en Rabassa Healthcare Centre.
Institut d'investigació Sanitària Illes Balears.
Medicine (Baltimore). 2020 Apr;99(17):e19769. doi: 10.1097/MD.0000000000019769.
High blood pressure is the leading modifiable risk factor for cardiovascular disease, and is associated with high morbidity and mortality and with significant health care costs for individuals and society. However, fewer than half of the patients with hypertension receiving pharmacological treatment have adequate blood pressure control. The main reasons for this are therapeutic inertia, lack of adherence to treatment, and unhealthy lifestyle (i.e., excess dietary fat and salt, sedentary lifestyle, and overweight). Cardiovascular risk and mortality are greater in hypertensive patients who are receiving treatment but have suboptimal control of blood pressure.
METHODS/DESIGN: This is a multicentre, parallel, 2-arm, single-blind (outcome assessor), controled, cluster-randomized clinical trial. General practitioners and nurses will be randomly allocated to the intervention group (self-management of antihypertensive medication, self-measurement of blood pressure, hypocaloric and low sodium diet, and physical exercise) or the control group (regular clinical practice). A total of 424 patients in primary care centers who use 2 or more antihypertensive drugs and blood pressure of at least 130/80 during 24-hambulatory blood pressure monitoring will be recruited. The primary outcome is systolic blood pressure at 12 months. The secondary outcomes are blood pressure control (<140/90 mm Hg); quality of life (EuroQol 5D); direct health care costs; adherence to use of antihypertensive medication; and cardiovascular risk (REGICOR and SCORE scales).
This trial will be conducted in the primary care setting and will evaluate the impact of a multifactorial intervention consisting of self-management of blood pressure, antihypertensive medications, and lifestyle modifications (hypocaloric and low sodium diet and physical exercise).
高血压是心血管疾病主要的可改变风险因素,与高发病率、高死亡率相关,给个人和社会带来巨大的医疗成本。然而,接受药物治疗的高血压患者中,血压得到充分控制的不到一半。主要原因是治疗惰性、治疗依从性差以及不健康的生活方式(即饮食中脂肪和盐过量、久坐不动的生活方式以及超重)。接受治疗但血压控制不佳的高血压患者心血管风险和死亡率更高。
方法/设计:这是一项多中心、平行、双臂、单盲(结果评估者)、对照、整群随机临床试验。全科医生和护士将被随机分配到干预组(抗高血压药物自我管理、血压自我测量、低热量和低钠饮食以及体育锻炼)或对照组(常规临床实践)。将招募424名在基层医疗中心使用两种或更多抗高血压药物且在24小时动态血压监测期间血压至少为130/80的患者。主要结局是12个月时的收缩压。次要结局包括血压控制(<140/90 mmHg);生活质量(欧洲五维健康量表);直接医疗成本;抗高血压药物的使用依从性;以及心血管风险(REGICOR和SCORE量表)。
本试验将在基层医疗环境中进行,评估由血压自我管理、抗高血压药物以及生活方式改变(低热量和低钠饮食以及体育锻炼)组成的多因素干预的影响。